IL17A and psoriasis: The present study showed that alantolactone decreased the mRNA levels of TNF-α, IL-6, IL-1β, IL-8, IL-17A, and IL-23, thereby suppressing Th1- and Th17-mediated cytokines and improving IMQ-induced psoriasis-like skin lesions and inflammation status in mice.